Moreover, ALA depletes Oct-4 and β-catenin by reducing the levels of p-AKT, thereby inhibiting epithelial–mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) cells [47]. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.